Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2021-001385-38-IT
EUCTR2021-001385-38-IT
Active, not recruiting
Phase 1

RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA NEEDING RADIATION THERAPY ON THYROID SITE - WIN-HYPO2021

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI0 sites51 target enrollmentAugust 30, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Enrollment
51
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 30, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Any patient with medulloblastoma, Hodgkin/non\-Hodgkin Lymphoma BEFORE RADIOTHERAPY (RT) PLANNING INCLUDING THYROID PARENCHYMA without previous primary or secondary hypothyroidism;
  • •2\.Written informed consent prior to any study\-specific analysis and/or data collection.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 19
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •1\.Any patient with medulloblastoma, Hodgkin/non\-Hodgkin Lymphoma after radiotherapy including thyroid parenchyma;
  • •2\.Not signed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021Hodgkin and non Hodgkin lymphoma, MedulloblastomaTherapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-512642-42-00Fondazione IRCCS Istituto Nazionale Dei Tumori65
Recruiting
Not Applicable
Radiation Protection Effects of Metformin in Prostate CancerProstate cancer.Malignant neoplasm of prostate
IRCT20170307032933N3Ahvaz University of Medical Sciences60
Not yet recruiting
Not Applicable
In this study the Sun Protection Factor of SPF will be determined.
CTRI/2019/01/017283Sami Labs Limited
Completed
Not Applicable
A study to check the sun protection benefits
CTRI/2023/02/049856nilever Industries Pvt Ltd10
Completed
Phase 2
A study to determine the protection factor of a test product against sun rays.
CTRI/2021/04/032696ITC Life Sciences Technology Centre20